RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line
treatment of patients with metastatic papillary carcinoma of the kidney.